Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan

OBJECTIVES: To evaluate the safety and effectiveness of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA) in real-world clinical settings in Japan. METHODS: Paediatric patients with sJIA initiating TCZ between April 2008 and February 2012 and those previously enrolled...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokota, Shumpei, Itoh, Yasuhiko, Morio, Tomohiro, Origasa, Hideki, Sumitomo, Naokata, Tomobe, Minako, Tanaka, Kunihiko, Minota, Seiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5013079/
https://www.ncbi.nlm.nih.gov/pubmed/26644233
http://dx.doi.org/10.1136/annrheumdis-2015-207818

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5013079/
https://www.ncbi.nlm.nih.gov/pubmed/26644233
http://dx.doi.org/10.1136/annrheumdis-2015-207818

Ejemplares similares